Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | TDP2 | O95551 | 3/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997999 | 0.82 | TRPV1 (0.37) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 | |
| SCHEMBL4093348 | 0.76 | CTSS (0.39) | CTSSCTSK | |
| SCHEMBL4430107 | 0.76 | CTSS (0.37) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 | |
| SCHEMBL5438324 | 0.75 | ALDH1A2 (0.38) | CTSSALDH1A2ALDH1A3CTSK | |
| SCHEMBL2235680 | 0.75 | CTSS (0.36) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 | |
| SCHEMBL3169031 | 0.74 | CTSS (0.36) | CTSSCYP11B2USP14CTSK | |
| SCHEMBL4284241 | 0.74 | PDE10A (0.37) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 | |
| SCHEMBL4426575 | 0.74 | CTSS (0.36) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 | |
| SCHEMBL3169024 | 0.74 | CTSS (0.36) | CTSSCYP11B2USP14CTSK | |
| SCHEMBL5428589 | 0.73 | ALDH1A2 (0.37) | TRPV1CTSSTDP2ALDH1A2ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885CTSS 4006/4885TDP2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.